Submodule
Aqueous Humor, Intraocular Pressure, and Optic Nerve Risk
Glaucoma is progressive optic neuropathy. Intraocular pressure is the major modifiable risk factor, but damage depends on susceptibility, baseline structure, visual function, pressure pattern, and time.
- Ciliary production
- Trabecular outflow
- Uveoscleral outflow
- Optic nerve progression
Carbonic anhydrase, beta, and alpha 2 targets
Major pressure-dependent pathway
Prostaglandin analog pathway
Pressure interacts with susceptibility and time
Follow aqueous humor flow
The ciliary processes produce aqueous humor, which moves through the pupil into the anterior chamber. It exits mainly through the trabecular meshwork and Schlemm canal, with an additional uveoscleral pathway through ciliary muscle spaces.
Separate open and closed angle mechanisms
Open-angle disease has an anatomically accessible angle with impaired outflow or optic nerve vulnerability. Angle closure involves mechanical obstruction of the drainage angle and may become an emergency. A pressure-lowering medicine does not replace definitive angle evaluation.
Individualize target pressure
A target is a working range chosen from untreated pressure, damage severity, life expectancy, corneal and measurement context, risk factors, and rate of progression. It must be revised if the optic nerve or visual field worsens despite reaching the previous target.
Measure structure and function
Pressure fluctuates and does not directly report neuronal survival. Serial optic nerve examination, retinal nerve fiber imaging, visual fields, gonioscopy when indicated, and adherence assessment reveal whether treatment protects vision.
Quick check
Submodule
Prostaglandin Analogs and Related Agents
Latanoprost, travoprost, tafluprost, bimatoprost, and latanoprostene bunod lower pressure primarily by increasing outflow, with meaningful local and product-specific safety differences.
- FP receptor signaling
- Uveoscleral outflow
- Pigmentation and adnexal effects
- Inflammation, macular, and corneal risks
Once-daily product-specific use
Hyperemia and adnexal changes
Pigmentation and periorbital change
Risk assessment before selection
Increase outflow
Prostaglandin F pathway agents remodel extracellular matrix and increase uveoscleral outflow. Latanoprostene bunod also releases nitric oxide, which can influence trabecular outflow. The exact dose and storage instructions remain product specific.
Counsel about visible change
Iris pigmentation can increase gradually and may be permanent. Eyelash length, thickness, number, pigmentation, and direction can change, while eyelid skin and periorbital tissues may also change. Unilateral treatment can produce noticeable asymmetry.
Respect inflammation and retinal context
Use requires caution according to the product in patients with active intraocular inflammation, macular edema risk, or a history of herpetic keratitis. New pain, photophobia, vision decline, or marked redness requires prompt evaluation rather than automatic continuation.
Avoid more frequent self-dosing
For latanoprost, dosing more often than recommended can reduce the pressure-lowering effect. Missed-dose instructions and administration timing should follow the exact product. More drops do not create proportionally more benefit.
Quick check
Submodule
Beta Blockers, Alpha-2 Agonists, and Carbonic Anhydrase Inhibitors
Topical products can reach systemic circulation. Timolol, brimonidine, dorzolamide, and brinzolamide therefore require whole-patient medication and disease review.
- Ophthalmic beta blockade
- Alpha-2 agonism
- Topical carbonic anhydrase inhibition
- Systemic absorption
Systemic heart and airway effects
CNS depression and allergy
Sulfonamide and corneal considerations
Reduce nasolacrimal systemic exposure
Use timolol with systemic beta-blocker caution
Timolol reduces aqueous production through nonselective beta blockade. Ophthalmic exposure can cause bradycardia, heart block, heart failure worsening, hypotension, bronchospasm, and reduced beta-2 rescue response. Asthma and specified conduction or cardiac conditions are major label constraints.
Use brimonidine with age and CNS caution
Brimonidine is an alpha-2 agonist that lowers production and may increase uveoscleral outflow. Fatigue, somnolence, dry mouth, allergy, and hypotension can occur. It is contraindicated in children younger than two years, and young children can have profound CNS depression.
Use topical carbonic anhydrase inhibitors as sulfonamides
Dorzolamide and brinzolamide inhibit ciliary carbonic anhydrase and reduce bicarbonate-dependent fluid secretion. Topical delivery does not prevent systemic absorption. Review severe sulfonamide reactions, corneal endothelial risk, kidney context, and concurrent oral carbonic anhydrase inhibition.
Reduce nasolacrimal exposure
After a drop, gently closing the eyelid and applying punctal pressure can reduce drainage into the nose and systemic absorption. This technique lowers but does not eliminate systemic risk. One properly placed drop is generally enough for the conjunctival sac.
Quick check
Submodule
Rho Kinase, Cholinergic, Laser, and Surgical Outflow
Trabecular outflow can be changed pharmacologically, with laser, or by creating new drainage pathways. The choice depends on mechanism, progression, burden, and anatomy.
- Rho kinase inhibition
- Pilocarpine and miosis
- Selective laser trabeculoplasty
- Incisional and minimally invasive procedures
Trabecular outflow and hyperemia
Meshwork tension with miosis
Medication alternative or partner
Escalate when progression outruns control
Relax trabecular resistance
Netarsudil inhibits Rho kinase and improves conventional outflow, with additional effects on episcleral venous pressure and production described for the product. Conjunctival hyperemia, corneal verticillata, instillation pain, and conjunctival hemorrhage are notable local effects.
Use pilocarpine by mechanism
Muscarinic M3 activation contracts ciliary muscle and can open trabecular spaces while producing miosis and accommodative spasm. Headache, brow ache, reduced night vision, retinal concerns, and systemic cholinergic effects limit broad chronic use.
Use laser as treatment, not failure
Selective laser trabeculoplasty targets pigmented trabecular cells and can be initial or adjunctive therapy in appropriate open-angle disease. Effect may diminish, repeatability and anatomy vary, and early pressure response still requires monitoring.
Create a new pathway when needed
Trabeculectomy, drainage devices, and minimally invasive glaucoma procedures alter outflow through different routes and risk profiles. Surgery becomes appropriate when the probability of vision loss exceeds the burden and risk of intervention.
Quick check
Submodule
Selection, Combination, and Progression Monitoring
The best regimen reaches an individualized pressure target, slows progression, fits systemic disease, minimizes local toxicity, and can actually be administered over years.
- Target pressure
- Class selection
- Combination and duplication
- Adherence and escalation
Baseline damage and rate
Structure and function over time
Comorbidity and adherence
Progression changes the plan
Choose a mechanism that fits the patient
Prostaglandin pathway therapy often offers strong once-daily pressure reduction, but ocular history and visible changes matter. Beta blockers may be unsuitable in airway or conduction disease. Alpha-2 agonists and carbonic anhydrase inhibitors have age, allergy, kidney, corneal, and adherence considerations.
Avoid silent ingredient duplication
Fixed-combination drops reduce bottle burden but can hide duplicate timolol, brimonidine, or carbonic anhydrase inhibitor exposure when another product is added. Reconcile active ingredients rather than brand names or cap colors.
Interpret apparent failure
Before adding therapy, verify diagnosis, target, technique, timing relative to pressure measurement, missed doses, bottle access, contamination, storage, preservative intolerance, and whether the medicine reaches the eye.
Escalate to protect vision
If confirmed progression continues, lower the target and consider another mechanism, laser, or surgery according to angle anatomy and risk. A comfortable pressure number does not justify delay when structural or functional loss is documented.
Quick check
Submodule
Ophthalmic Administration and Safety
Technique determines delivered dose, contamination risk, washout, adherence, and systemic spillover. Device ability is part of prescribing.
- One-drop delivery
- Tip contamination
- Punctal occlusion
- Contact lenses and product separation
Avoid tip contamination
More volume adds spillover
Reduce nasolacrimal absorption
Prevent washout and dosing error
Deliver one controlled drop
Wash hands, tilt the head, create a lower-lid pocket, and place one drop without touching the tip to the eye, lashes, skin, or fingers. The conjunctival sac has limited capacity, so extra volume mainly increases drainage and systemic exposure.
Close and occlude
Close the eyelid gently without squeezing and apply pressure near the inner canthus for the product-recommended interval. This reduces nasolacrimal drainage. Blinking forcefully can pump medicine toward the nose.
Separate products and contact lenses
When multiple ophthalmic products are used, separate them according to label instructions to reduce washout. Ointments generally follow drops. Remove and reinsert contact lenses according to the product's preservative and timing instructions.
Solve physical and cognitive barriers
Tremor, arthritis, poor vision, weakness, cognition, bottle stiffness, and complex schedules can prevent accurate use. Observe technique, simplify where possible, add an appropriate device or caregiver, and verify refill access.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.